Bristol Myers announces results from Phase 2 study evaluating BMS-986278

Bristol Myers Squibb announced results from a Phase 2 study evaluating BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 antagonist in patients with progressive pulmonary fibrosis, or PPF. The study showed that twice-daily administration of 60 mg of BMS-986278 over 26 weeks reduced the rate of decline in percent predicted forced vital capacity by 69% compared to placebo. These data will be presented during the Abstracts Leading to Evolution in Respiratory Medicine Trials, or ALERT, session 1 at the European Respiratory Society 2023 International Congress held September 9-13. In the PPF cohort, treatment with 60 mg of BMS-986278 led to a 69% relative reduction in the rate of change in ppFVC versus placebo in the while-on-treatment analysis and a 74% relative reduction versus placebo in the treatment policy analysis. In the 30 mg group, a 42% relative reduction was observed in the while-on-treatment analysis and a 37% relative reduction was observed in the treatment policy analysis. The treatment effect was consistent in the presence or absence of background antifibrotics and usual interstitial pneumonia pattern. “The results from this innovative study investigating idiopathic and progressive pulmonary fibrosis give us unprecedented insights that will inform our scientific understanding of pulmonary fibrosis and the role of LPA1 inhibition. Our industry-leading drug discovery and development capabilities and collective results from this Phase 2 study provide us the expertise and confidence to support continued development of BMS-986278 in our global Phase 3 ALOFT program in idiopathic and progressive pulmonary fibrosis,” said Jonathan Sadeh, MD, MSc, senior vice president of Immunology Development, Bristol Myers Squibb.